For example, the prognostic significance of IDH mutations may be secondary to their prevalence among younger patients, as age is a well-known prognostic factor in gliomas.5 In AML, the prognostic significance of IDH mutations is more ambiguous. This evidence concerns the gene IDH2 and acute myeloid leukemia.